Elsevier

The Lancet

Volume 343, Issue 8899, 19 March 1994, Pages 707-708
The Lancet

Short reports
Interleukin-10 production during septicaemia

https://doi.org/10.1016/S0140-6736(94)91584-9Get rights and content

References (9)

  • H. Ishida et al.

    Modified immunological status of anti-IL-10 treated mice

    Cell Immunol

    (1993)
  • Mp Glauser et al.

    Septic shock: pathogenesis

    Lancet

    (1991)
  • R. de Waal Malefyt et al.

    Interleukin-10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes

    J Exp Med

    (1991)
  • O. Pradier et al.

    Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide

    Eur J Immunol

    (1993)
There are more references available in the full text version of this article.

Cited by (312)

  • Immunotherapy in sepsis - brake or accelerate?

    2020, Pharmacology and Therapeutics
    Citation Excerpt :

    Sepsis involves not only excessive inflammation but also several molecular and cellular events that support immunosuppression (Hotchkiss, Monneret, & Payen, 2013b). One example is the release of anti-inflammatory mediators such as IL-10, IL-1 receptor antagonist (RA) or transforming growth factor beta (TGFβ) by immune cells (Cavaillon, Adib-Conquy, Fitting, Adrie, & Payen, 2003; Goldie et al., 1995; Marchant et al., 1994; Marie, Cavaillon, & Losser, 1996). While these processes may help rebalance the immune system, over-exuberant immune suppression can be harmful to critically ill patients by allowing for the development of secondary infections and subsequent multi-organ failure (Gentile et al., 2012).

View all citing articles on Scopus
View full text